Are all-oral-based induction combinations the future for AML treatment?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Jeffrey Lancet, Moffit Cancer Center, Tampa, US. We asked, Are all-oral-based induction combinations the future for acute myeloid leukemia treatment?

Lancet discusses the potential transition to all-oral-based induction regimens for the treatment of patients with acute myeloid leukemia, highlighting oral decitabine and cedazuridine plus venetoclax for older patients who are ineligible for intensive chemotherapy. He then highlights potential future novel combinations with oral targeted therapies, such as menin and isocitrate dehydrogenase inhibitors, and how they could expand the oral-based treatment options available to patients with targetable mutations. Lancet concludes by discussing potential challenges associated with all-oral-based regimens.